By: IPP Bureau
Last updated : April 24, 2025 12:51 pm
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
Syngene International Limited has reported consolidated financial results for the period ended March 31, 2025.
Syngene International has reported total income of Rs. 1036.9 crores during the period ended March 31, 2025 as compared to Rs.933 crores during the period ended March 31, 2024. The company reported total income of Rs. 962 crores during the period ended December 31, 2024.
Syngene International has posted net profit of Rs. 183.3 crores for the period ended March 31, 2025 as against net profit of Rs.188.6 crores for the period ended March 31, 2024. The company posted net profit of Rs. 131.1 crores for the period ended December 31, 2024.
For the financial year ended FY2025, Syngene International has reported total income of Rs. 3,714.2 crores as compared to Rs.3579.2 crores during the Financial Year ended March 31, 2024.
The company has posted net profit of Rs.496.2 crores for the Financial Year ended March 31, 2025 as against net profit of Rs.510 crores for the Financial Year ended March 31, 2024.
Commenting on the results, Peter Bains, Managing Director and CEO, Syngene International Limited, said, “Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time. At the EBITDA level growth was 9% year-on-year reflecting good underlying fundamentals. The highlight of the quarter was the acquisition of a state-of-the-art biologics manufacturing facility in the US, strengthening Syngene’s position in the fast-growing biologics CDMO sector and providing a strategic foothold in the US market. Our biologics CDMO business witnessed robust growth supported by commercial manufacturing alongside new development projects. High conversion of pilot projects into full programs in discovery services supported the growth in our research division.
“The full year results, led by reported revenue growth of 4%, are in line with our January guidance, reflecting a resilient performance in a challenging year. After a muted first half, driven by a sectoral downturn in US biotech funding, we are encouraged to see a return to growth in the second half of the year.
“Looking at the year ahead, while the wider global market dynamics remain uncertain, we expect the business momentum to continue with pipeline build in both small and large molecules, supported by new pilot programs and conversion of existing pilots in discovery services. On an underlying basis for fiscal year 2026, we expect revenue growth in the early teens reflecting a broad-based growth across research, development and manufacturing services. Adjusted for inventory balancing in large molecule commercial manufacturing at client level, the reported revenue growth is likely to be at mid-single digit.
“The mid-term indicators for the CRDMO sector remain positive and I am confident that Syngene’s diverse and well-balanced portfolio across research, development and manufacturing services positions us well to navigate the dynamics and continue our growth story.”
Deepak Jain, Chief Financial Officer, Syngene International Limited, said, “Q4 growth was broad based across research, development and manufacturing services, underpinning full year growth of 4% on a reported basis and 2% in constant currency. Operating EBITDA growth came in at 3% maintaining a margin of 29% reflecting a sharp focus on operational efficiencies and cost optimization programs. We continued to make strategic investments to enhance our capabilities and capacities across business while maintaining a strong balance sheet and an improved net cash position.
“For fiscal year 2025, the Board of Directors has recommended a final dividend of Rs. 1.25 per share, subject to shareholders approval.
“Looking ahead into the next financial year, we expect the momentum to continue, with reported revenue growth at the mid-single digit level. As we bring the new biologics manufacturing facilities into operations, the additional operating costs and depreciation will impact margins. With this, we expect EBITDA margin to moderate from current levels to the mid-twenties and year-on-year decline in profit after tax.”